It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
NOABSTRACT
Graves' disease (GD) is an autoimmune disease that affects the thyroid and the eyes. Graves' ophthalmopathy (GO), an autoimmune disease, usually appears 18 months after GD diagnosis. Clinical activity and disease severity determine the strategy, with steroid treatment recommended during active disease progression.
This review aims to provide an overview of steroid therapy in the treatment of Graves' ophthalmopathy, discussing its efficacy, protocols, and considerations.
We reviewed the papers focusing on management recommendations and assessed peer-reviewed publications using the following keywords: "Graves' disease", "Graves' ophthalmopathy", "Graves' orbitopathy", "glucocorticoids".
Steroid therapy, especially glucocorticoids, is a primary pharmacologic intervention for clinically active GO. Intravenous administration has shown superior outcomes compared to oral administration, with a recommended protocol that uses a cumulative dose of 4.5 grams methylprednisolone. High-dose systemic glucocorticoids possess anti-inflammatory and immunosuppressive characteristics and are efficacious in managing moderate to severe active GO. Second-line therapies, such as methylprednisolone monotherapy or in com-bination with cyclosporine, may be considered.
Graves' ophthalmopathy re-quires intravenous glucocorticoids during the active phase. Intravenous glucocorticoids are more effective and better tolerated than oral glucocorticoids. Patients with Graves' ophthalmopathy require individualized treatment plans that address contraindications and side effects to improve outcomes and quality of life.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
2 Endocrinology, Metabolism and Diabetes Division, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University – Makassar, Indonesia
3 Nephrology and Hypertension Division, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University – Makassar, Indonesia
4 Pulmonary Disease and Critical Care Medicine Division, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University – Makassar, Indonesia